A mitochondrial transport protein builds up in the muscle of people with type 2 diabetes — and exercise brings it down

Type 2 diabetes affects more than 500 million people worldwide, and skeletal muscle insulin resistance is one of its earliest and most rate-limiting defects: muscle accounts for roughly 85% of whole-body glucose disposal at rest. A team led by researchers at the University of Oklahoma's Harold Hamm Diabetes Center and Cleveland Clinic, publishing in Nature Communications on October 19, 2026 (Heintz, Dantas, Taylor and colleagues), asked whether a mitochondrial movement protein called Miro1 (mitochondrial Rho GTPase 1) helps explain why diabetic muscle stops responding to insulin.

In a cross-sectional clinical study, volunteers — healthy-weight, with obesity without diabetes, or with obesity and type 2 diabetes (12 per group) — underwent fasted muscle biopsies and gold-standard hyperinsulinemic-euglycemic clamp testing. Miro1 protein had accumulated in the muscle mitochondria of the diabetes group only, and its level correlated negatively with measured insulin sensitivity.

Why does Miro1 pile up in diabetic muscle?

The study traces the pile-up to a signaling failure. In healthy muscle, insulin prompts the kinase AKT to move into mitochondria, where it interacts with Miro1 and keeps its level in check. In patients with type 2 diabetes, insulin-stimulated mitochondrial AKT phosphorylation (at threonine 308) was nearly absent — and blocking AKT in muscle cells caused Miro1 to accumulate rapidly. The same accumulation appeared in three mouse models of obesity and hyperglycemia (a high fat/fructose/cholesterol diet, and two genetic models), arguing it is a feature of the diabetic state rather than of diet alone.

What happens when Miro1 is removed from muscle?

Deleting Miro1 specifically from mouse skeletal muscle — or from cultured C2C12 muscle cells — increased mitochondrial oxidative phosphorylation capacity and electron transport chain efficiency, raised AKT and AS160 phosphorylation, increased GLUT4 transporter movement to the cell surface, and improved glucose disposal. In other words, excess Miro1 appears to actively constrain both the muscle's energy machinery and its insulin signaling — a non-canonical role for a protein previously studied mostly for moving mitochondria around inside cells.

Can exercise change Miro1 in people?

Yes, in this study's randomized comparison: exercise training in patients with obesity and type 2 diabetes lowered skeletal muscle Miro1, relieved mitochondrial hyper-fragmentation, and improved oxidative capacity and lipid handling alongside insulin sensitivity. That gives the finding a practical edge — the protein is not fixed. The limits are equally clear: the human data are cross-sectional associations plus an exercise intervention, not a Miro1-targeting drug trial; no therapy aimed at Miro1 has been tested in people, and whether lowering Miro1 directly (rather than through exercise's many effects) improves human glucose control is unproven.

Where the evidence stands

• Established: Skeletal muscle insulin resistance is a primary defect in type 2 diabetes, diabetic muscle shows mitochondrial defects, and exercise training improves muscle mitochondrial function and insulin sensitivity.
• Preliminary: In human biopsies (12 per group), mouse models and muscle cells (Nature Communications, Oct 19, 2026), Miro1 accumulated in diabetic muscle via defective mitochondrial AKT signaling; muscle-specific Miro1 deletion improved respiration and glucose disposal in mice, and exercise training lowered Miro1 in patients.
• Absent: Any human trial of a Miro1-targeting drug, and proof that lowering Miro1 directly — rather than through exercise — improves glucose control in people.